By engaging Outcome, you gain a trusted and committed partner who intimately understands your company, your sector and your potential investors and acquirers. We will bring our expertise to bear, enhance your value and guide you all the way to a successful transaction.
They understood our technology and business as well as anyone.
I have worked with Outcome Capital on multiple, complex transactions. They bring strategic insights and operational experience to the table like no other investment bankers I have ever worked with.
Every member of the Outcome team, from Managing Directors to Analysts, is passionate about what they do, providing a unique perspective to strategy development and transactional execution. We believe this is a key aspect of Outcome’s strong record of success.
former CEOs, entrepreneurs, institutional investors, bankers, scientists and clinicians — bringing together a diversity of outlooks, experiences, and knowledge that enable Outcome to develop creative insights and secure the best outcomes for its clients.
Dr. Ben-Joseph is a Founder and Managing Partner with Outcome Capital. He brings a unique combination of executive, entrepreneurial, scientific and transactional experience to Outcome Capital and is passionate about assisting cutting-edge life sciences companies in enhancing their strategic value and developing a path to a successful liquidity.
Dr. Ben-Joseph also serves on the Board of Directors of life sciences companies: XableCath, a clinical stage medical device innovator developing cost-effective treatment options for peripheral and cardiovascular disease and ELIOS Vision, a commercial stage ExTra Laser trabeculotomy for the treatment of glaucoma. He also serves as Mentor At the MIT Innovation Fund, assisting young entrepreneurs in defining market-aligned path for novel technologies.
Before joining Outcome Capital, Dr. Ben-Joseph was Managing Director at Boston Equity Advisors, a boutique investment banking firm focusing on private equity and merger and acquisition in the therapeutic medical technology sector. Prior to that, Dr. Ben-Joseph was an Executive-in-Residence at Oxford Bioscience Partners, a life sciences venture capital firm, and CEO and co-founder of Caliber Therapeutics, a company engaged in the development of catheter-based drug delivery products for the intervention of atherosclerotic diseases. His past managerial and entrepreneurial positions also include President and CEO at Deep Vein Medical, an early stage medtech company dedicated to treating deep venous reflux in patients suffering from chronic venous insufficiency, President and CEO of X-Cell Medical, a clinical stage drug/device convergence company engaged in the development of novel stent-based anti-restenotic drugs, President of Ester Neurosciences, a clinical stage biotech company engaged in the development of novel compounds for the treatment of neurological diseases, and co-founder and CEO of Biolight Phototherapy, a company engaged in the development of laser-based medical devices for the treatment of dermatological disorders and allergies.
His academic appointments include Assistant Professor at the Departments of Radiology and Neuroscience at the University of Michigan, a Visiting Associate Professor at Tokushima University in Japan and a Visiting Scientist at Pfizer. Dr. Ben-Joseph has published numerous peer-review scientific papers, as well as industry publications and has received numerous awards and scholarships.
Dr. Ben-Joseph graduated with Honors from Imperial College London and received his Ph.D. from the University of Cambridge. He completed his post-doctoral training at the University of Michigan and received an MBA magna cum laude from the University of Bradford. He is a FINRA Securities Representative holding Series 7, 63 and 79 registration and a Registered Securities Principal holding a Series 24.
Arnie Freedman is a Founder and Managing Partner with Outcome Capital. Mr. Freedman has extensive experience in private equity financing, mergers and acquisitions and preferred securities. His primary focus is in life sciences offerings, including medical devices, diagnostics and drug development. He assists companies with pre-IPO and early stage financing and prepares companies for the rigor required for merger and acquisition activity.
Mr. Freedman has been involved in the management of entrepreneurial businesses for over 25 years, previously as a co-founder and principal in Boston Equity Advisors, LLC, a registered broker-dealer and boutique investment-banking firm. In this company, Mr. Freedman focused on M&A transactions, private placements of debt and equity with institutional investors from the venture capital, private equity, family-foundation and hedge fund community. He uses his knowledge of the private placement process to help clients prepare for the scrutiny of potential investors by conducting a pre-financing review of client operations and corporate structure, recommending changes, assisting management in implementing those changes and preparing documentation investors require including business plans, marketing and insurance reimbursement strategies and financial models. Arnie brings his operating expertise to bear on the advice and counsel he provides to his clients.
Prior to Boston Equity Advisors, Mr. Freedman was the founder and CEO of Rustel, a Russian/American satellite telecommunications company, where he developed an extensive connection to the European investment community. He worked closely and collaborated with investment banking advisors Deutsche Morgan Grenfell, Salomon Brothers, and Creditanstalt International Advisors.
Mr. Freedman is a graduate with honors from the University of Massachusetts. He is a FINRA Registered Securities Representative holding a Series 7, 63 and 79 and a Registered Securities Principal, Series 24.
Dr. Ellen Baron brings extensive experience in the private placement of securities for life science companies with deep domain expertise across multiple disciplines in pharmaceutical and biotechnology industries. Ellen is committed to the success of emerging growth companies bringing nearly 30 years of industry experience with proven deal execution and a unique access to the people, resources and markets that are vital for success. She has been involved in the raise of more than $150M of investment capital and has $2B in deals to her credit from her days in pharma and biotech.
Dr. Baron currently serves on the Board of Directors of Tetragenetics Inc., a Boston-based biotech pioneering antibodies to ion channels, Sixth Element Capital, a UK-based oncology focused venture capital fund and SFH, a Maine-based nutraceutical company.
Dr. Baron was most recently a Managing Director at Healthios Capital Markets, LLC, leading their firm’s biopharmaceutical practice. Prior to that she spent 9 years as Partner at Oxford Bioscience Partners, a Boston-based life science venture capital firm where she led numerous therapeutic and diagnostic investments within the $1 billion portfolio of 149 companies.
Ellen previously served as Senior Vice President, Business Development at Human Genome Sciences, a publicly traded biopharmaceutical company where she was responsible for all business functions of the Company including corporate partnering, licensing and investor interface.
Ellen previously had spent 20 years at Schering-Plough Corporation in both Research and Development and Business Development. She has over 30 years of operating and investment expertise across the spectrum of the pharmaceutical and biotechnology industries, with particular emphasis in oncology, neurology, and infectious disease. Ellen holds a Ph.D. in Microbiology from Georgetown University School of Medicine and a post-doctorate at the Public Health Research Institute in New York. She is a FINRA Registered Securities Representative holding Series 79 and 63 registration.
Dr. Mieyal is a Managing Director with over 20 years of public and private early-stage life sciences investment and operational experience.
Prior to joining Outcome Capital, Dr. Mieyal served as Managing Director of Life Sciences Investments at Wexford Capital. He was previously a Vice President of Wechsler & Co., a broker-dealer and proprietary investment firm.
Dr. Mieyal has served as a director or observer on the boards of numerous life sciences companies, including AZTherapies, Danube Pharmaceuticals, Ellipse Technologies, ElMinda Ltd, GlobeImmune, Interventional Spine, Invuity (IVTY), MiCardia, Microbiogen Pty, Nephros (NEPH), Nile Therapeutics (NLTX), OncoVista (OVIT), Onset Medical, Optiscan Biomedical, Pear Tree Pharmaceuticals, Rebound Therapeutics, Reverse Medical, Shape Memory Therapeutics, Sophono, Tigris Pharmaceuticals, and Viseon.
From 2010 to 2012, Dr. Mieyal served as the CEO of publicly-traded Nephros, Inc. (NEPH), during which period, he completed strategic in-licensing and out-licensing transactions for the company’s products and led negotiations with the FDA which resulted in the clearance of the company’s hemodiafiltration system in the U.S.
Dr. Mieyal earned his Ph.D. in Pharmacology from New York Medical College and his B.A. in Chemistry and Psychology from Case Western Reserve University. He is a Chartered Financial Analyst and a member of the CFA Institute, the CFA Society of Boston, and the New York Academy of Sciences. He is a FINRA Registered Securities Representative holding Series 79, 7 and 63 registrations.
Dr. Panigone is a Managing Director of Outcome Capital based in Europe. With over 25 years of public and private life science company experience, she brings a unique combination of scientific, operational and transactional expertise. She has an extensive track record of financing, M&A transactions and participation in the listing of companies.
Dr. Panigone has broad experience across the life science value chain, having served in C-level positions in a variety of companies, including NLS Pharmaceutics (NASDAQ:NLSP), Bracco and Quintiles. As Chief Operating Officer at NLS Pharmaceutics, she drove the company’s lead asset through IND and a successful Phase II, which triggered investment to support a pivotal study.
Dr. Panigone was previously a Managing Director at I-Bankers Direct, an equity funding web platform, and an Advisor for I-Bankers Securities group, a US investment banking firm. She formerly served as Investment Director at BSI Healthcapital, a life science focused venture capital firm, and was responsible for venture investments in the merchant division of the Swiss bank BSI (now EGF). Dr. Panigone has served as a Director on the boards of multiple US- and EU-based companies, including GlobeImmune, Visioncare Ophthalmic Technologies, Ikonsys, AlphaVax and SpectAquilar, bringing several to an exit transaction.
Dr. Panigone was a Laboratory Head of the Nanotechnology Lab of the IFOM Institute (FIRC Institute of Molecular Oncology) at the European Institute of Oncology. She also served as Strategic & Business Advisor for the Swiss Institute for Cellular Therapies (SCIT) and is currently serving as a Senior Director at XoVenture, a global network of entrepreneurs in the Life Sciences, and Start-Up Coach for the Swiss government (Innosuisse).
She earned her Ph.D. in Molecular Oncology from Degli Studi University and her MBA from SDA Bocconi School of Management. She completed Fellowships at the University of Washington and the National Cancer Institute (INT) in Milan.
Karl Hess is a Managing Director with Outcome Capital and leads its HealthTech and digital health practices. Having interacted extensively with hundreds of digital health companies over the years, as well as with dozens of their healthcare and life sciences investors, customers and partners, Karl has become known as a leading subject matter expert on the topics of successful digital health business models, commercialization, investment and technologies. From pharmaceuticals to medical devices and software (SaMD), digital health tools and therapeutics and health optimization and population health management platform technologies to entire care delivery ecosystems, Karl has helped design, develop and commercialize dozens of innovative products and services across the healthcare and life sciences industries, representing hundreds of millions of dollars in incremental revenues and more than $20B in value-unlocking transactions.
Prior to Outcome Capital, Karl was most recently Interim President and CEO of Texas Health | Aetna, a joint venture (and commercial health plan entity) of Texas Health Resources and Aetna, a CVS Health Company. Karl was formerly CEO of Kalico Partners, LLC, a technology-enabled provider and population health management organization (PHMO), and Chief Digital Health Officer of Collain Healthcare, a former subsidiary of LG CNS. Prior to Collain, Karl held the role of Vice President, Corporate Development at Welltok, Inc., a digital health and wellness company revolutionizing the way population health managers align consumer actions and behaviors with the right incentives and rewards. In one of his earliest digital health endeavors, Karl was a key member of the commercial team at Welldoc, Inc., helping to bring Welldoc’s BlueStar platform to market, one of the world’s first, and most successful, digital therapeutics. Earlier in his career, Karl worked for several start-up and Fortune 500 molecular diagnostics, biopharmaceutical, medical technology companies and consulting firms including Genentech, Becton Dickinson and PRTM, principally across product development and management, and market, business and corporate development, licensing and M&A.
Over the years Karl has had the opportunity to participate in two successful exits as an entrepreneur and work on and lead projects for 9 of the Top 20 pharmaceutical companies, 11 of the Top 20 medical device firms and 4 of the Top 25 PE firms, and has had global management responsibilities of leading extended teams of up to 500 and ~$300MM P&L.
Karl began his career as a life sciences researcher, conducting pre-clinical cancer and human genetics research at The University of Texas Southwestern Medical Center, and biotechnology R&D for what are now several subsidiaries of Thermo Fisher Scientific, Inc. Karl received a B.A. in Biology and an M.B.A. both from The University of Texas at Austin. He is a FINRA Registered Securities Representative holding Series 79 and 63 registrations.
Steve Holstein serves as Managing Director, Head of Business Development, at Outcome Capital. He is responsible for building, driving, and leading the firm’s global business development, which includes research, sales and marketing.
Steve has over over 30 years of experience in the technology, investing, and insurance industries as a strategy, marketing, product and distribution leader.
Prior to joining Outcome Capital, Steve served as Head of Global Business Development for Gordon Brothers and Enterprise Chief Marketing Officer & Head of Retail at Folio Financial, where he successfully led customer acquisition, turnaround, and technology upgrade programs. Prior to that, Steve held senior roles including Chief Marketing Officer, Division Head, and Chief e-Business Officer at Covestor, now Interactive Brokers, Guardian, and MassMutual Financial Group.
Steve holds a MBA from Boston University, and a BA in economics from Clark University. Steve is active with several non-profits including MassChallenge, SFNet, and more than 20 years riding the Pan Mass Challenge for the Dana-Farber Cancer Institute.
Craig is a Director of Life Sciences at Outcome Capital and brings corporate and commercial expertise in the diagnostic and life science space. A business leader with extensive global experience in the life sciences and healthcare industries, Craig has held various executive positions from start-up companies through large, well-established international corporations. His success building commercially viable and sustainable enterprises has lead to the completion of several successful acquisitions over the past several years including Caliper Life Sciences, HandyLab and BioHelix. In addition to his role as Vice President of Life Sciences at Outcome Capital, Craig also volunteers with mentoring activities for Women in Biotech and as an Advisor to Springboard Enterprises.
Craig’s scientific background and business experience spans sales, marketing, business development, licensing, strategic partnerships and operations. His key successes include developing and launching new businesses at Fisher Healthcare, HandyLab, Becton Dickinson and Caliper Life Sciences within the diagnostic market space. Craig’s knowledge of the diagnostic and life science tools markets has allowed him to develop markets across the globe and leverage strategic partnerships to further market expansion for many of his clients.
Craig holds a Bachelor of Science from the University of Wisconsin – Madison and a Master of Science from Yale University. He is a FINRA Registered Securities Representative holding Series 79 and 63.
Thomas F. Busby is a Director at Outcome Capital, having joined the Firm in 2015. Drawing from transactional experience spanning the breadth of life science verticals, Mr. Busby’s primary coverage and focus spans the medical device, digital health, and life sciences services segments.
Mr. Busby has advised dozens of senior management teams and Boards on a variety of complex strategic issues, ranging from transaction process considerations to valuation and transaction structure, value proposition communication and buyer analysis, along with the plethora of managerial challenges faced in executing complex corporate events. Devoted to the industry he serves, Mr. Busby has been published in leading industry publications, including: MedTech Strategist, Life Science Leader, and The Pharma Letter. Mr. Busby has also served as a panelist, moderator and judge for numerous industry events and is a Board Member of HealthTech Build, a Boston-based digital health innovation group. He also served as an External Advisory Board Member for the UMASS Chan Medical School Bridge Fund.
Prior to his career in investment banking, Mr. Busby pursued his passion for the public service and non-profit sectors. He raised significant capital for many education-related ventures while holding management and leadership positions.
Mr. Busby completed his BS and MBA at Suffolk University on full academic scholarship and was voted President of the School’s business association. Committed to giving back, Mr. Busby served as a two-term President for the University’s Alumni Board of Directors. He resides on Massachusetts’ South Shore with his wife and daughter. Mr. Busby is a FINRA Registered Securities Representative holding his SIE, Series 79 and 63.
David Hausler serves as Director of Finance & Operations at Outcome Capital. David brings over 25 years of extensive accounting and operational experience in the alternative investment industry ranging from start-ups to registered investment advisors managing over $1B across multiple asset classes.
Prior to joining Outcome Capital, David served as Chief Financial Officer & Managing Principal for Little Harbors Advisors where he was responsible for all accounting and operational matters for Little Harbor’s exchange traded funds and management company.
Previously, David was Chief Financial and Compliance Officer at Helios Partners Fund Management where he was responsible for oversight of all accounting, regulatory, compliance, administrative and marketing matters for the Helios Funds. Prior to Helios Partners, David was the Controller at Sandler Capital, a registered investment adviser managing $1.2 billion in both hedge funds and private equity funds. He was responsible for all accounting and back-office administration for four hedge funds and led the implementation of the fund’s portfolio accounting systems. Prior to his tenure at Sandler Capital, David worked as a Controller at Centre Partners, a registered middle market private equity investment firm with a capital base of $1.8 billion. In this capacity, he led the launch of the Accounting and Finance Group and established the accounting and operational infrastructure that supported Centre Partners and its private equity funds. Prior to Centre Partners, David was the Accounting Manager at Smith Management, a highly diversified private family office, where he helped restructure their complex in-house financial and accounting operations.
David graduated with a BS in Accounting from SUNY College at Old Westbury.
Dr. Nicholas Frame is a Senior Vice President in the life sciences practice at Outcome Capital bringing a unique combination of scientific, strategic, and transactional expertise. Nick is trained biophysics and during his time in research published multiple first-author manuscripts and received NIH training grants and university awards to support his work. Having shifted his interest and attention to life sciences companies and the innovation within industry, Nick is focused on advising biopharma, medical device, and services companies on their go-to-market strategies as it relates to financing, partnering and M&A transactions. Based on his experience advising clients in numerous M&A, licensing and financing, Nick has been published in leading industry journals including Trends in Biotechnology and In Vivo.
Nick continues to support others navigating the transition from academia to industry roles, having mentored numerous undergraduate and doctoral students from leading programs including Johns Hopkins University, Boston University, and Harvard University, among others.
Nick holds a B.A. from Johns Hopkins University in biophysics and earned his Ph.D. in biophysics from Boston University School of Medicine. Nick is a FINRA Registered Securities Representative holding his Series 7, 79 and 63.
Dr. Michael Casasanta is a Senior Associate at Outcome Capital. He trained as a research scientist with broad exposure to cutting-edge infectious disease, and oncology-based technologies.
Dr. Casasanta is a published author with numerous peer-reviewed manuscripts in addition to his significant contributions in several multi-million-dollar NIH-funded grants supporting his research. During his time in research, Dr. Casasanta developed a passion to enrich the personal and professional lives of his colleagues. He served in the Graduate Student Assembly of Virginia Tech and the Student Council of the Microscopy Society of America to provide community building and professional development events for both students and early career professionals. Subsequent to his academic studies, Michael served as a Venture Fellow at Nodes Advisors AG, a European-based corporate advisory firm. There, Dr. Casasanta led due diligence processes evaluating the scientific and economic potential of emerging biotechnology companies while assisting in the preparation of transactional materials for the Fund’s portfolio companies.
Dr. Casasanta received dual B.S degrees in Biology and Biochemistry and earned his Ph.D. in Biochemistry from Virginia Tech’s flagship campus in Blacksburg, VA. He is a FINRA Registered Securities Representative holding Series 7, 79 and 63 registrations.
Carey Gallant is a Associate in Outcome Capital’s life sciences practice assisting the team in support of a wide range of M&A, corporate finance, and advisory mandates.
Prior to Outcome, Carey was an associate within LifeSci Partners’ Investor Relations and Capital Markets Advisory groups. While at LifeSci, Carey assisted with a variety of strategic consulting efforts for early- and late-stage healthcare and life sciences companies via tailor-made market research and competitive market analysis. Preceding his role at LifeSci, Carey conducted scientific research as a Senior Research Associate at Synlogic Therapeutics and a Research Associate at Minerva Biotechnologies. His research revolved around the design, development, and execution of various cellular based assays for specific biomarkers within immune-oncology and inflammatory disease settings. Carey’s scientific research leveraged the anti-proliferative effects of Minerva’s proprietary small molecules and, later, the probiotic and therapeutic advantages of Synlogic’s genetically engineered E. coli Nissle (EcN).
Carey received a B.S. in biomedical engineering from the University of Vermont and an MBA /MSF dual degree from Boston College’s Carroll School of Management . In addition to his formal coursework, Carey has also completed valuation and financial modeling course with Wall Street Prep. He is a FINRA Registered Securities Representative holding Series 79 registration.
Elena Bonetti is a Senior Analyst in Outcome Capital’s life science practice . Within her role at Outcome, Elena facilitates extensive market research across multiple verticals including medical device, biotechnology, digital health, diagnostics and life science services. Drawing from deep knowledge of financial markets, Elena assists Outcome’s clients in market sizing, market share analysis and growth outlooks to inform strategic positioning and align technologies with their respective markets. Elena also directly supports Outcome’s clients in their administrative and process-related needs.
Prior to joining Outcome, Elena was a legislative intern for the Commonwealth of Massachusetts. As an active community member and lifelong North End resident, Elena currently serves as a member and financial secretary to several nonprofit and benefit organizations in the Boston area.
Elena completed her BSBA in Finance with a minor in Business Law at Suffolk University, graduating Summa Cum Laude as a Sawyer Business School Honors Scholar, and is pursuing an MBA degree at Boston College. She is a FINRA Registered Securities Representative holding Series 79 and 63 registration.
Fahid Naseer is a Senior Analyst at Outcome Capital who draws from a unique combination of M&A, strategic advisory, and scientific experiences. Before business school, Fahid has a breadth of experience in business and corporate development as well as life science commercial strategy consulting.
Prior to Outcome Capital, Fahid was an analyst at Jupiter Life Science Consulting assisting in drug product launch, pricing, and market access commercial strategy development. Prior to Jupiter, Fahid was in the corporate development group at Merrimack Pharmaceuticals where he assessed potential drug targets, M&A opportunities, and strategic finance initiatives. Fahid began his career with the business development team at Parexel International where he was responsible for customer strategy, and subsequently transitioned to Vertex where he focused on cystic fibrosis drug launches in Europe. After his time in life sciences business and corporate development, Fahid entered the investment banking industry as a Senior Analyst in Progress Partners’ technology group, before transitioning to Outcome to focus exclusively on life sciences and healthcare transactions. Fahid has extensive experience as a life sciences researcher conducting oncology research a Massachusetts General Hospital as well as computational chemistry research at New Jersey Medical School.
Fahid received a B.S. in biochemistry from the University of Massachusetts, Boston, a M.S. in biomedical science from Rutgers New Jersey Medical School, and an MBA from Babson College. In addition to his formal coursework, Fahid has also completed valuation and financial modeling seminars with leading financial services providers.
Dr. Roisin O’Brien is a Senior Analyst at Outcome Capital. Trained formally as a scientist, Dr. O’Brien leverages her scientific and research expertise in support of the Firm’s clients throughout all life science verticals.
Prior to her investment banking career, Dr. O’Brien focused her doctoral studies on characterizing the molecular mechanisms of CRISPR-Cas genome editing technologies through complementary structural and biophysical techniques. She published multiple peer-reviewed, first-author manuscripts in such journals including Nature Communications and Molecular Cell. Alongside her PhD studies, Dr. O’Brien consulted for the University of Texas at Austin Office of Technology and Commercialization life sciences division. Roisin worked with licensing specialists to effectively market technologies developed at UT Austin and facilitate licensing agreements with biotech/pharma corporations. In addition, Roisin advised numerous pre-revenue and post-revenue venture start-ups on successful go-to-market strategies through Jon Brumley Texas Ventures.
Dr. O’Brien holds a B.A. degree in Biochemistry from the University of San Diego and earned her PhD in Biochemistry from the University of Texas at Austin. She is a FINRA Registered Securities Representative holding Series 79 and 63 registration.
Dr. Thomas Bellio is an Investment Banking Analyst at Outcome Capital. He trained formally as a research scientist with extensive work in the fields of neuroscience and bioinformatics. Dr. Bellio utilizes his substantial life science research background to support all aspects of Outcome Capital’s operations.
Prior to starting at Outcome Capital, Thomas’ doctoral studies focused on behavioral and molecular characterization of the effects of perinatal choline supplementation within Alzheimer’s Disease mouse models. He received a prestigious National Science Foundation fellowship in Neurophotonics that enabled him to learn cutting-edge techniques in the field of neurophotonics throughout his doctoral education. Dr. Bellio is a published author of multiple peer-reviewed publications, has presented his work at numerous national and international conferences, and has received multiple awards for his scientific accomplishments.
Dr. Bellio holds a B.S. degree in Neuroscience from the Moreau Honors Program at Stonehill College and earned his PhD in Biomedical Neuroscience-Pathology from the Boston University School of Medicine.
Erik is an Investment Banking Analyst Intern at Outcome Capital, leveraging his diverse background in scientific research and business analytics to support the Firm’s initiatives in investment banking and strategic advisory.
Before joining Outcome Capital, Erik interned at BioCentury’s Business Intelligence Group, refining his analytical skills and gaining a deep understanding of the biotechnology landscape. Additionally, he served as an Analyst for Boston University’s Office of Technology Development, facilitating the translation from scientific innovation to commercialization.
With specialized training in immunology research, Erik’s focus is on B cell biology, particularly in the realm of autoimmune and lymphoproliferative diseases prevalent in primary immune deficiencies. Previously, he contributed to a variety of cutting-edge projects as an ORISE Research Fellow at the U.S. Army Medical Research Institute of Chemical Defense.
Erik earned a B.S. in Biological Sciences from Davidson College and a M.S. in Biotechnology from Johns Hopkins University. Currently, he is pursuing a Ph.D. in Molecular & Translational Medicine at Boston University School of Medicine, having secured funding through an NIH-sponsored Immunology Training Program.
Tyler Steed is an Investment Banking Analyst Intern at Outcome Capital. He leverages his experience across the private capital markets to support the team in its M&A advisory mandates and business development initiatives.
Prior to joining Outcome Capital, Tyler was with Skyway Capital Markets, a lower middle-market investment bank, where he supported the firm on a diverse range of M&A advisory mandates. Before his time at Skyway, Tyler was with Brighton House Associates assisting on the firm’s capital raising initiatives.
Tyler received a B.S. in Finance with a Capital Markets concentration and a minor in Economics from Bentley University. In addition to his formal education, Tyler has completed courses in financial modeling, merger analysis, and valuation through Financial Edge Training.
Curtis is a Research and Business Development Analyst at Outcome Capital. Within his role, Curtis is responsible for conducting market research, analyzing data, and developing strategies that help the firm grow and succeed. He works closely with our management team to identify opportunities for expansion, assess market trends, and devise new business initiatives.
Prior to joining Outcome Capital, Curtis was with Clarus Capital, a middle market private lender, where he supported the firm’s business development and investment management teams. Preceding this, Curtis worked in insurance, consumer banking, and small business banking at TD Bank.
Curtis is currently pursuing a BSBA degree from Suffolk University’s Sawyer Business School with a double major in Finance and Economics.
Dr. Juniewicz serves as Senior Advisor with Outcome Capital’s Biotechnology and Pharma practices. He brings extensive scientific, strategic and operational expertise in public and private life science companies.
He is currently Senior Director of Business Development at Takeda Pharmaceuticals Oncology Business Unit focusing on late-stage clinical oncology opportunities. Prior to that, Dr. Juniewicz served as Senior Director for Oncology Search & Evaluation in Takeda’s Center for External Innovation (CEI). In this role, he led the scouting of external oncology opportunities as well scientific and technical due diligence for several transactions including, among others, MD Anderson, Turnstone Biologics, Memorial Sloan Kettering Cancer Center, Shattuck Labs, Molecular Templates, Maverick Therapeutics, as well as the Japan licensing of cabozantinib (Exelixis) and niraparib (Tesaro) and the merger and acquisition of Ariad Pharmaceuticals. Based on his accomplishments Paul was awarded the title of Distinguished Research Fellow in Oncology in 2019.
Dr. Juniewicz started his professional career with Sterling Drug as a bench research scientist and then took a position as Oncology Project Manager overseeing several oncology projects. Following the acquisition of Sterling Drug by Sanofi, Paul rose to the role of VP Oncology Project Management and oversaw the development of oncology projects that resulted in global regulatory approvals for several agents including oxaliplatin for colorectal cancer, rasburicase for tumor lysis syndrome and aflibercept for colorectal cancer.
Dr. Juniewicz numerous accomplishments include over 100 external opportunities reviewed with 10+ entering due diligences each year, development of Takeda’s oncology strategy, oncology scouting and partnering activities at AACR, ASCO & ASH, JP Morgan and BIO meetings.
Dr. Juniewicz received a BS from Rutgers University, an MS and a Ph.D. from North Carolina State University. He completed his postdoctoral training at Johns Hopkins University.
Dr. Montgomery serves as Senior Advisor to Outcome Capital’s Biotechnology and Pharma practice. He brings extensive expertise in bench-top molecular biology research, clinical practice, drug development and marketing in both biotech and Big Pharma. He has developed several database solutions in the field of project management, resulting in two J&J IMAGE awards, and has spoken at multiple events on the successful application of software and data management solutions to real world medical problems. He has designed and run both US and Global Phase 2, 3 and 3b trials in cardiovascular disease, peripheral vascular disease, stroke, inflammatory diseases and the first Phase 4 Registry in Polycythemia Vera, REVEAL. He holds a key patent in the use of JAK1 inhibitors. Dr. Montgomery also led Incyte Corporation’s Global Medical Affairs department that he helped create. He has been CMO of both Caduceus Communications LLC, a clinical communications company and Lead Horse Technologies Inc., an AI company. He currently sits on the PhRMA Foundation Translational Medicine Grant Review Board and is a Co-Founder of Stable Solutions LLC, a medical and machine learning consultancy.
In addition to his experience in the biotech and pharma sectors, Dr. Montgomery’s medical and research career includes attending physician at Parkland and Dallas Veterans Hospitals, Cardiology Research Fellow at Washington University School of Medicine and Associate Professor at Temple Medical School Department of Anatomy & Cell Biology. Dr. Montgomery is widely published in peer-reviewed medical and scientific journals on various topics including stroke, peripheral and arterial vascular disease, dermatology and oncology. He received his MD from Columbia University College of Physicians and BSc degree from McGill University.
Chuck Morrison serves as a Senior Advisor at Outcome Capital’s diagnostics and biotechnology practices. He brings significant expertise and a track record in successfully structuring, negotiating and executing acquisitions, licensing, partnerships, and distribution transactions. Chuck is a business development executive with over thirty years of life science, biotechnology and diagnostic expertise, including 13 years of corporate business development. He is a leader in the life science sector with proven business acumen, international experience, integrity, strategic vision and focus on execution. Known for driving results and overcoming difficult challenges.
Chuck is currently a non-executive Board Member for GenePOC, Inc., a molecular diagnostic company developing point-of-care platforms for the rapid detection of infectious diseases (recently acquired by Meridian Bioscience). He is also Head of Business Development at Proteomics International, Perth, Australia. PI has developed a proprietary mass spectrometry biomarker discovery platform and has recently discovered biomarkers for the diagnosis of diabetic kidney disease. Previously, Chuck held various managerial positions at PerkinElmer, NEN Life Sciences and DuPont Medical Products.
Chuck is currently providing strategic consulting services to early-stage and smaller biotech companies, positioning toward merger & acquisitions, partnerships, licensing and joint ventures, as well as team building, product commercialization and carving out a path to commercialization.
Dr. Petti serves as Senior Advisor to Outcome Capital’s diagnostics and digital health practices. She is a health technology executive and diagnostics expert with a unique combination of clinical, scientific and operational expertise, focusing her efforts in the molecular diagnostics, genomics and digital health verticles. She serves as a strategic, interim Chief Medical Officer providing companies with top-down market perspective and an extensive thought leader network. Dr. Petti supports strategic corporate activities related to technology assessments, clinical trial and regulatory strategies, and pathways to commercialization. She has assisted numerous companies across the value-add chain, successfully facilitating private equity financings, government contracts and merger and acquisition transactions amounting to hundreds of millions of dollars. She serves on the Advisory Boards for Pathogenomix, Life365, and Becton Dickinson. As an entrepreneur supporting innovative early-stage technologies, Dr. Petti founded MoDx.ai, a knowledge domain platform integrating diagnostics, digital health and Artificial Intelligence.
Among her senior executive roles, Dr. Petti served as Global Head at Novartis Diagnostics where she was responsible for expanding global markets for their core products and building R&D teams for three de novo franchises. As Chief Health Officer at Ancestry, Dr. Petti built a direct-to-consumer genetic testing portfolio and served on the executive team that led to private equity investments at enterprise value of $2.6 billion. She also led ARUP Infectious Diseases Laboratory, one of the country’s largest infectious diseases laboratories and pioneered research in DNA sequencing.
Dr. Petti shares her expertise and leadership with several global non-profit organizations and regulatory agencies, including having chaired committees for the Clinical and Laboratory Standards Institute; served as program lead for Infectious Diseases Society of America; and advised the FDA Microbiology Device Committee. Previously, Dr. Petti was a Governor Appointee and member of the Board of Directors for Utah’s Science, Technology and Research (USTAR) Initiative. Committed to underserved populations, she received the College of American Pathologists’ Humanitarian Award for her work in providing diagnostic testing in sub-Saharan Africa;was awarded the 2015 ASM-IUSSTF Indo-US Professorship in Microbiology; and served as 2019 Visiting Professor to Infectious Diseases Institute, Kampala, Uganda.
As a practicing infectious diseases clinician, Dr. Petti provides a critically relevant understanding of healthcare drivers for adoption of new technologies. She has held academic appointments as Professor of Medicine and Pathology at leading institutions; and is frequently invited to speak on topics in clinical diagnostics, healthtech innovations, global health, and women’s entrepreneurship. Dr. Petti holds an AB from Harvard University and MD from Duke University. She is an internist, and dual board certified in infectious diseases and medical microbiology.
Dr. Popper serves as Senior Advisor in Outcome Capital’s molecular diagnostics and biotechnology practices. She brings significant expertise and track record in positioning novel technologies toward successful implementation and commercialization. Dr. Popper is also the Co-Founder and President of Popper and Company, a specialty consulting firm focused in diagnostics, information-generating tools and healthcare analytics, where she and her team leverage their extensive knowledge of the trends and forces shaping the life sciences industry and its participants.
Dr. Popper has more than 25 years of hands-on biotech/life sciences operating experience. An internist and pathologist, she combines medical and scientific perspective with knowledge gained from managing a wide spectrum of life sciences businesses in diagnostics, devices and drug discovery. Her business management experience in both Fortune 500 and start-up settings – and extensive track record creating strategic and business partnerships in the biotech arena – is key to the insights she provides to her clients.
During a 10-year career at Becton Dickinson (NYSE: BDX), Dr. Popper’s global responsibilities included clinical affairs, marketing, strategy, and business development. She was the founding General Manager of BDGene, a start-up focused, with its partner Millennium Pharmaceuticals, on development of novel cancer diagnostics. Subsequently, she was the Chief Business Officer for MDS Proteomics, a drug discovery company with operations in the U.S., Canada and Europe.
Dr. Popper received her medical degree from the University of the Witwatersrand (South Africa) and her M.P.H. from Johns Hopkins University (Baltimore). She completed her residencies in internal medicine and in pathology at Johns Hopkins. Dr. Popper is and Advisory Board member of the Bloomberg Johns Hopkins School and Public Health and inHealth, the Hopkins Precision Medicine Initiative. She is a board member of Diversigen (a microbiome-based company) and LBT Innovations (an Australian AI-based lab automation company).
Dr. Torfs serves as a Senior Advisor at Outcome Capital’s diagnostic and medical device practices. He brings signifiant expertise and track record in marketing and business development with over 20 years experience. Dr. Torfs is passionate about propelling innovative products and technologies to drive change through increased access, quality of care and accurate diagnostics where and when it matters most.
Dr. Torfs operational experience spans from early-stage innovative companies to large multi-national strategic players where he launched multiple products in the EMEA region and worldwide. Many of those products resulted in a paradigm shift in diagnostic practices, based on health economic evidence and improved diagnostics for better patient outcomes.
Dr. Torfs is also the Founder and President of DIATOR BVBA, a consulting firm supporting early stage marketing during product development, guiding early market access and devising Go-To-Market strategies. DIATOR also provides interim management and strategic consulting services to early-stage biotech and diagnostic companies.
Herbert holds an MSc in Biology and Ph.D. in Physiology and Molecular Biology, both from the Catholic University of Leuven, Belgium, and an EMBA from Hult-Ashridge Business school London Campus.
Dr. Ramakrishnan serves as a Senior Advisor in Outcome Capital’s biotechnology and medtech practices. He brings significant scientific and entrepreneurial expertise in positioning novel technologies toward successful investments. Dr. Ramakrishnan is also a Director at UConn Ventures. In this role, he is focused on helping early-stage faculty startups in the life sciences space and also works with companies at the Technology Incubator Program (TIP). He has extensive experience in private equity and venture capital investing, starting his career at Intellectual Ventures, a $6B fund based in Seattle, where he focused on healthcare investments. He then served as President of AxioSonic, a medical device startup that was focused on treating chronic sinus infections non-invasively. Prior to joining UConn Ventures, he was the Managing Partner, New Ventures at Ventech Solutions, where he focused on private equity transactions. He has extensive experience in medical device development, intellectual property management, and fund raising for early-stage companies.
Dr. Ramakrishnan received his B.S. degree in Biophysics from Osmania University, his M.S. degree in Life Sciences from University of Hyderabad and his Ph.D. in Computational Biology from Brigham Young University. He completed his Post-Doctoral Fellowship at Oregon Health and Science University in electrophysiology.
Mr. Jiang is the Founder and CEO of Shanghai YAFO Capital. He has over 15 years Wall Street experience in investment banking, M&A, and investment of in both Israeli and American technology companies. He has worked with US and China investment banks. He was the Chinese General Manager of ISI Group (NY) and Managing Director of ISI research. Before that, he was a senior research analyst at Roth Capital (LA) where he was involved in multiple cross-border transactions. When at Xiangcai Securities, a leading investment bank in Shanghai, Sean was the executive director, responsible for advising foreign institutional investors in China’s stock markets. Mr. Jiang is now a visiting professor at Concordia University (Wisconsin). He received his MBA from Pepperdine University, MA in finance from Fudan University, and BA in Economics from Central South University of China. He is a CFA Charter holder.
Mr. Tao is a Managing Partner of YAFO Capital and the Head of our U.S. Business. Mr. Tao has more than 15 years experience as an analyst and consultant working with public and private companies in North America and China across a variety of technology sectors. He has extensive knowledge on market analysis, business development, due diligence, and operations for U.S. – China cross-border transactions. He previously worked at William O’neil + Co. where he developed its Chinese operations and oversaw Chinese research. Before that, he was Director of Chinese research and senior research analyst at Roth Capital Partners where he supported over $2 billion cross-border equity financings. Mr. Tao is a CFA Charter holder and has a MBA from University of California, Riverside.
Mr. Zheng is the Managing Director of YAFO Capital. He has been focusing on cross-border investment in healthcare sector since the beginning of his career life. Mr. Zheng has been involved in 30+ global life science financing transactions and advisory assignments and has led the team to close numerous deals. Before joining YAFO Capital, He was an equity research analyst covering the Chinese healthcare sector at Roth Capital Partners, a full-service investment banking firm headquartered in California. He was also a Angle investor of neurointerventional medtech which is now a Hillhouse Capital portfolio company. Mr. Zheng received a MS in Finance from Vanderbilt University in the US and a BS in Finance from the University of International Business and Economics in Beijing.
Mr. Yao Nengong graduated from Medical College of Shanghai JiaoTong University in 1990. After two years of being an OB doctor, Mr. Yao entered into the medical care industry in China. Before he joined in YAFO capital, he worked 7 years (1993-2000) in Astra China, the predecessor of AstraZeneca China, and oversaw government affair, marketing and BD in China. Also he has co-established the Cyberpharm Investment Co., Ltd. and Sino-Octa Holdings Limited, focusing on the medical care field in China. He is responsible for the Sales and Marketing and BD in the company.
Mr. Ye has more than 25+ years’ experience in Pharmaceutical industry, including the supply Chain as well as commercial and Business development. He served as Head of Business Development and Alliance Management in GSK China and was a member of GSK China Leadership Team. He also had 15years in Manufacturing in pharmaceutical industry. He was the Engineering and project manager for GE Healthcare Shanghai Plant, was a member of Plant Management Team. He also worked for Schering-Plough and Shanghai Number 6 pharmaceutical company for various positions.
Qi Li is an accomplished professional with seven years of experience in the pharmaceutical industry analysis and investment banking, specializing in mergers and acquisitions (M&A) and licensing. With a strong background in the sector, Qi has successfully analyzed and connected with over 300 pharmaceutical companies in China, building a vast network within the industry. Additionally, Qi has been extensively involved in more than 20 global life science licensing transactions, showcasing a deep understanding of the intricacies of these deals. Qi holds a Bachelor’s degree from San Jose State University. In their role as the BD Director, Qi brings a wealth of knowledge and expertise to drive successful partnerships and business development initiatives.